Johnson & Johnson Vision announced the availability of the Tecnis Synergy IOL for patients in Europe, Australia, and New Zealand. The Tecnis Synergy IOL creates a new standard in presbyopia-correcting IOL (PC-IOL) technology, allowing patients to experience continuous high-contrast vision from far through near, even in low-light conditions. The launch was announced at the European Society of Cataract and Refractive Surgeons (ESCRS) in Paris, where Johnson & Johnson Vision is also presenting new clinical data on the Tecnis Synergy IOL.
“As ophthalmic pioneers, we took on the challenge to develop an IOL that would give patients the clear, continuous range of vision they want, from far to near, day to night,” Tom Frinzi, worldwide president, surgical, at Johnson & Johnson Vision, said in a company news release. “Today, thanks to the ingenuity of our team of researchers and scientists, we stay true to our legacy of innovation with the introduction of the Tecnis Synergy IOL, our most advanced IOL solution yet, which we believe will redefine the industry standard for IOL quality and performance.”
The Tecnis Synergy IOL provides a broad range of continuous vision covering from distance to 33 cm; eliminates the visual gaps present in trifocal and other multifocal technology, offering patients the freedom to focus within the range; continues to deliver superior performance in low-light conditions; and demonstrates reduction in halo intensity for tasks like night driving, as demonstrated in clinical simulations.
“The Tecnis Synergy IOL is a game-changer,” Dr. Francesco Carones, MD, medical director and physician CEO of Carones Vision in Milan, Italy, said in the news release. “I am delighted with the results my patients have had. With some lenses, patients can find it hard to focus on objects at certain points, but the continuous vision provided by Tecnis Synergy IOL smooths out those visual ‘gaps.’ Best of all, the lens continues to perform, even as light dwindles.”
The Tecnis Synergy IOL has CE Mark approval and is now commercially available across Europe, including the United Kingdom, Italy, France, Spain, and Germany. It is also available in Australia and New Zealand. This product is not currently approved or commercially available in other countries.